Shares of Moderna surged to lead S&P 500 gainers in early afternoon trading Tuesday, hours after the Food and Drug ...

Moderna, Inc. (NASDAQ:MRNA) shares soared to the top of the S&P 500 gainers in early afternoon trading on May 20, surging by ...

The company is seeking authorisation for a fourth dose of SpikeVax to any adult who has received an initial booster of any of the authorised or approved COVID-19 vaccines. Unlike Pfizer ...

According to a Moderna statement, the booster stimulated a greater than ... still ongoing however about the possibility of offering a fourth shot more widely to protect against a resurgence ...

In late morning trading, shares of Moderna were up 11.2% at $29.24, Pfizer rose 2.2% to $23.51 and Novavax shares were up 2.2% at $7.91. Makary and Prasad said they expect the FDA will be able to ...

WASHINGTON -- Moderna submitted its application to the U.S. Food and Drug Administration for emergency use authorization of its updated COVID-19 vaccine booster for use in people age 18 and older ...

People ages 6 months and up can get either a Pfizer-BioNTech or Moderna booster. Moderna. This is an mRNA vaccine given in two doses, 4 to 8 weeks apart to people ages 6 months and older.

4 and BA.5 subvariants, Moderna has unveiled promising new data for its prospect. On Monday, the mRNA specialist said its omicron-containing bivalent booster elicited higher neutralizing antibody ...

Once you’ve finished your primary series, you may be eligible for a booster shot. Most people receive either a Pfizer or Moderna booster. A Johnson & Johnson booster does exist, but it’s ...

Despite this week's climb, shares of Moderna have lost about a third of their value this year so far Shares of Moderna surged to lead S&P 500 gainers in early afternoon trading Tuesday ...

Moderna, Inc. (NASDAQ ... a sizable majority of the population would still be able to obtain annual booster shots, even though their availability this fall would be restricted to older adults ...